Alphabet company Verily is partnering with Emory Healthcare to deploy new solutions to help improve cost-effectiveness, operational efficiency and quality.
Johnson & Johnson is acquiring the remaining stake in Verb Surgical Inc. from Verily, Alphabet Inc.’s life sciences division.
Verily announced a strategic collaboration deal with Novartis, Otsuka, Pfizer, Sanofi, and six major health systems.
Artificial intelligence (AI) is increasingly seen as a tool in biopharma and life sciences to improve drug development. There is a bit of a resource lag because AI is expensive. For example, Google/Alphabet owns an AI laboratory called DeepMind. Google acquired DeepMind in 2014 for a reported $650 million. Google, as one of the largest corporations on Earth, is very interested in the use of AI and health care.
Gilead Sciences Inc. will partner with privately held insitro to develop therapies for a fatty liver disease called NASH.
Researchers with Cortexyme published research in the journal Science Advances describing the role of Porphyromonas gingivalis, a bacteria that causes gingivitis, to Alzheimer’s disease.
Google’s Verily will team up with ResMed, a company that specializes in treating sleep disorders, to launch a joint business venture to address sleep apnea and other sleeping disorders.
Google is betting on the potential of European biotech companies to deliver life-changing drugs by investing alongside Swiss company Novartis in a new $300 million fund run by leading life sciences investment firm Medicxi.
Verily, Google’s life sciences division, aims to eliminate the threat of the mosquito-borne Zika virus by figuring out how to prevent the pesky pests from reproducing.